SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

CIK: 0001910264 · Show all filings

Period: Q2 2023 (← Previous) (Next →)

Filing Date: Aug 10, 2023

Total Value ($000): $231,908 (100.0% shares, 0.0% debt)

Holdings (6)

ACLX ARCELLX INC 53.8%

Value ($000) $124,792 Shares 3,946,630 Est. Cost $16.72 Unrealized +128.7%

DSGN DESIGN THERAPEUTICS INC 17.7%

Value ($000) $41,117 Shares 6,526,476 Est. Cost $16.67 Unrealized -63.3%

MLYS MINERALYS THERAPEUTICS INC 13.2%

Value ($000) $30,598 Shares 1,794,600 Est. Cost $16.83 Unrealized -11.2%

SPRY ARS PHARMACEUTICALS INC 11.6%

Value ($000) $26,886 Shares 4,012,903 Est. Cost $6.79 Unrealized -2.2%

— EFFECTOR THERAPEUTICS INC 2.4%

Value ($000) $5,594 Shares 6,822,114 Est. Cost $8.28 Unrealized —

NKTX NKARTA INC 1.3%

Value ($000) $2,920 Shares 1,333,333 Est. Cost $13.12 Unrealized -66.5%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	ARCELLX INC	3,946,630	$124,792	53.8%	$16.72	+128.7%	COMMON STOCK	03940C100
DSGN	DESIGN THERAPEUTICS INC	6,526,476	$41,117	17.7%	$16.67	-63.3%	COM	25056L103
MLYS	MINERALYS THERAPEUTICS INC	1,794,600	$30,598	13.2%	$16.83	-11.2%	COM	603170101
SPRY	ARS PHARMACEUTICALS INC	4,012,903	$26,886	11.6%	$6.79	-2.2%	COM	82835W108
—	EFFECTOR THERAPEUTICS INC	6,822,114	$5,594	2.4%	$8.28	—	COM	28202V108
NKTX	NKARTA INC	1,333,333	$2,920	1.3%	$13.12	-66.5%	COM	65487U108